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Introduction
Severe aortic valve regurgitation (AR) is associated with a long asymptomatic period during which the left ventricle (LV) progressively dilates and hypertrophies in response to a chronic volume overload. This process is accompanied by a decrease in LV function, occurrence of symptoms and eventually heart failure (4; 7). No drug has yet been clearly shown in humans to be effective to slow LV dilation, hypertrophy, and loss of systolic function or to have any impact on morbidity or mortality in chronic AR (5; 15) .
At the microscopic level, AR is associated with cardiomyocytes elongation and also believed by excessive but mostly non-collagen myocardial fibrosis (fibronectin) (6; 23) .
Although gene expression profiling in LV eccentric hypertrophy resulting from volume overload has been studied recently in an aortocaval fistula rat model (25) , very little is known about the mechanisms of LV hypertrophy and extracellular matrix remodeling associated with a more clinically common form of LV volume overload namely aortic valve regurgitation. Aorto-caval fistula models relate to a clinically rather rare complication of aortic aneurysm or secondary to abdominal trauma in humans (21) .
Moreover, aorto-caval fistulae result in a global form of volume overload affecting all right and left heart chambers resulting in rapid and massive congestive heart failure. On the other hand, chronic aortic valve regurgitation often secondary to rheumatic fever is a condition still very frequent in developing countries and in populations having nonadequate access to health care (3; 13; 20; 36) . Aorto-caval fistulae as well as mitral valve regurgitation are both characterized by a low pressure LV overload while aortic valve regurgitation represents a mixed form of volume overload with a component of pressure overload (10) . Contrarily to the natural evolution of aorto-caval fistula models, 5 we have shown that our model of chronic AR is associated with severe LV hypertrophy but moderate (and late) loss of function with a low rate of congestive heart failure (29; 31) . Significant LV fibrosis is present later in the evolution of this disease and is associated with increased mortality (31) . We hypothesize that in AR, activation of genes encoding collagens and non-collagens components of the extracellular matrix is a feature of this type of LV eccentric hypertrophy.
We present here the first study of LV gene expression profiling in an eccentric hypertrophy model caused by severe aortic valve regurgitation during the acute phase of LV remodeling two weeks post AR-inducing surgery in male Wistar rats. We have also investigated the LV expression of a subset of genes acutely modulated at later times (chronic period: 6 and 12 months).
Considering that we have previously shown that both the adrenergic and reninangiotensin systems are over-activated in our model of AR, we tested the effects on LV gene expression of a drug therapy consisting of a combination of a 1-adrenergic blocker (metoprolol) and an angiotensin II converting enzyme inhibitor (ACEi) (captopril), two drugs we have previously demonstrated to effectively slow LV hypertrophy and loss of systolic function in our model (14; 30; 32) . 6 Methods Animals: Male adult Wistar rats (300-350g body weight) were purchased from Charles River (Saint-Constant QC, Canada).
Acute study: Twelve animals were equally divided in two groups: Sham-operated (Sh2) and aortic regurgitation (AR2). Sacrifice was done two weeks after surgery.
Six-month study: Thirty-six animals were equally divided in three groups: Shamoperated (6 months (Sh26) AR (AR26) and treated AR (ART) animals receiving in their drinking water both captopril (100 mg/kg/day) and metoprolol (25 mg/kg/day) for six months starting two weeks after AR induction.
Twelve-month study: Thirty animals were divided in two groups: Sham-operated (Sh52; n=10), AR (AR52; n=20). This protocol was approved by the Université Laval's animal protection committee and was consistent with the recommendations of the Canadian Council on animal care.
Aortic regurgitation: AR was induced by retrograde puncture of the aortic valve leaflets under anesthesia as previously described (2; 29; 32) . Sham-operated animals had their right carotid artery cannulated under anesthesia without puncturing the aortic valve. AR was considered severe by echocardiography by the following criteria at the time of surgery: color-Doppler ratio of regurgitant jet width to LVOT diameter >50%, retrograde holo-diastolic flow in proximal descending aorta with end-diastolic velocity >18 cm/s, ratio of time-velocity integral of reversed diastolic flow to forward systolic flow in descending thoracic aorta >60% and acute increase in LV diastolic dimension during the surgical procedure. Echocardiographic criteria of AR severity had to be accompanied by 7 an acute drop of aortic diastolic pressure of at least 30% to qualify. Animals not meeting the echographic and hemodynamic criteria were not included in the study. Animals were clinically evaluated daily by experienced animal laboratory technicians for the presence of signs of heart failure (increased respiratory rate/distress and/or peripheral edema) and were weighed weekly. At the end of the protocol, surviving animals were sacrificed, hearts were quickly dissected and all cardiac chambers were weighed. Pieces of LV were snap-frozen in liquid nitrogen and kept at -80 o Celsius for further analysis while a mid-ventricular slice (~2-3 mm thick) was kept in RNAlater solution (Ambion, Austin TX) for RNA studies.
Echocardiography
A complete M-Mode, 2D and Doppler echocardiogram was performed on the animals under 1.5% inhaled isoflurane anesthesia using a 12 MHz probe with a Sonos 5500 echograph (Philips Medical Imaging, Andover, MA) immediately before and during surgery and at the end of the protocol. Left ventricular dimensions, wall thickness, ejection fraction, diastolic function, cardiac output (ejection volume in the left ventricular outflow tract X heart rate) were evaluated as previously reported (14; 33) . AR was semiquantified at each time-point as described in the previous section. Animals had to meet all the criteria of severe AR by semi-quantization at each time-point to remain included in the protocol.
Array experiments
Total RNA was extracted from stored tissues using Trizol (Invitrogen, Carlsbad, CA), and further purified on column with RNeasy MinElute (Qiagen, Valencia, CA). RNA 
Analysis of mRNA accumulation by quantitative RT-PCR
As previously described (31), LV RNA samples were diluted to 500ng/µl. One µl RNA (500 ng) was converted to cDNA using the QuantiTect® Reverse Transcription kit (Qiagen), a procedure which included a genomic DNA elimination step. The cDNA obtained was further diluted 11-fold with water prior to amplification (final concentration corresponding to 4.54 ng/µl of initial RNA). Five µl diluted cDNA were amplified in duplicate by Q-PCR in a Rotor-Gene TM thermal cycler (Corbett Life Science. Sydney, Australia), using QuantiTect® Primer Assays (pre-optimized specific primer pairs from 9 Qiagen; Table 1 ) and either QuantiTect® or QuantiFast® SYBR Green PCR kits (Qiagen). Each run included one tube with water only (no template control) and a series of three 10-fold dilutions of a representative cDNA sample to check efficiency of the amplification reactions. In the case of intronless genes, minus-RT control reactions were made on ten randomly chosen samples to ensure that genomic DNA did not yield significant amplification. The quantification of gene expression was based on the -2Ct method (22) . Briefly, mean Ct values of duplicates for each gene of interest were subtracted from the mean Ct value (hence Ct) of the control "housekeeping" gene cyclophilin A. The difference in the mean Cts between groups of rats (Ct) allows the calculation of relative levels of induction/repression of genes of interest.
Cardiomyocyte cross-sectional area (CSA) and evaluation of fibrosis:
Sections from paraffin-embedded mid-LV portions were stained using the TrichromeMasson staining. Three sections per slide from 10 animals per group were studied for the evaluation of cross sectional area (CSA) of the cardiomyocytes as previously described (19) . Total myocardial and peri-vascular fibrosis was also evaluated from the Trichrome-Masson stained LV midwall section as previously described (19) .
Other statistical analysis
Results are presented as mean ± SEM unless specified otherwise. Inter-group comparisons were done using one or two-way ANOVA and Tukey's post-test and intragroup comparisons with paired t tests. Statistical significance was set at a p<0.05. Data 10 and statistical analysis were performed using Graph Pad Prism version 4.02 for Windows, Graph Pad Software (San Diego CA).
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Results
All animals survived in the acute two-week study. Table 2 shows the findings at the time of sacrifice. As expected, severe aortic valve regurgitation induced a marked increase in heart weight which was almost totally due to left ventricle hypertrophy. Using echocardiography, this LV hypertrophy was characterized by clear chamber dilation (increased LV end-diastolic diameters and stroke volume and decreased relative wall thickness (RWT). During this acute 2-week phase, neither systolic function (Table 2) Tables 3 and 4 show results from the array study. As illustrated in the upper panel of figure 1 , general levels of gene expression tended to be increased in AR animals compared to sham-operated controls. For further analysis, we chose to discard genes displaying low levels of expression. In order to do so, we calculated the mean + 5 times the standard deviation of the signals obtained from the DNA chips of genes encoding for olfactory receptors as a threshold of minimal expression to be considered as meaningful. As illustrated in the middle panel of Figure 1 , around 16000 genes were excluded this way. We chose to arbitrarily fix the fold change levels between AR LV samples and sham controls to 1.5 times with a P value below 0.001 and a SAM d-score <-3 of >3 in order to consider a gene as regulated. The volcano plot in Figure 1 As listed in Table 3 and 4, respectively, we found 64 up-regulated genes (>1.5 fold change) in AR left ventricles compared to controls and 29 down regulated genes (<0.67 fold change).
As illustrated in Figure 2 , we found a good correlation (r 2 =0.79 and p<0.0001) between these results and those obtained from quantitative RT-PCR (qPCR) in terms of fold change for a subset of 20 genes (3 down-regulated, 4 non-regulated and 13 upregulated) studied using both techniques. However, the correlation between fold changes obtained for each gene by qPCR compared for the intensities of the signal on the DNA chip was also significant but less solid (r 2 =0.38 and p=0.003; not shown).
In this first step of our study, we performed gene profiling experiments on the LV from AR rats during a still very active and acute period of adaptation to a severe volume overload and observed the modulation of several genes. In order to see if this modulation was still present at later times in more chronic phases of the disease we chose to look at two later time points: 6 and 12 months. At 6 months, survival rate was 83% (10/12) but only 40% at 12 months (8/20; p<0.0001 vs. S52 group) in AR animals while all sham animals were still alive at both 6 and 12 months. Most of the animals died from sudden death and only one by heart failure as previously observed (31) . As shown in Table 5 , dilated LV hypertrophy was present in AR animals and systolic function as depicted be the ejection fraction parameter were still in the normal range (>50%) although significantly reduced compared to sham controls.
A subset of 19 genes was studied for their mRNA levels in the surviving AR animals and fold change comparison to their sham-operated counterparts was made at those three 13 time points (2, 26 and 52 weeks). As illustrated in Figure 3 , most of the genes studied were modulated similarly at the different time points.
Pharmaceutical strategies (-blockade, ACE inhibition) aiming at the adrenergic or the renin-angiotensin systems have been shown in this rat model to improve either survival or LV function or hypertrophy (30) (31) (32) . We therefore tested if we could observe benefits by combining these drugs and hopefully normalize the LV expression of various genes especially ones implicated in the control of fibrosis and markers of LV dysfunction such as ANP and BNP. As illustrated in the right column of Table 5 , the combination of a 1-adrenergic receptor blocker (metoprolol) and an angiotensin II converting enzyme inhibitor (captopril) did help slow LV hypertrophy and tended to improve systolic function. Moreover, we observed normalization of LV gene expression for Collagen Type I and III as well as for fibronectin and CTGF (Figure 4 ). In addition, levels of ANP, BNP and TGF2 were also reduced in AR animals by this drug combination. 14 
Discussion
We present in this study the first gene profiling of the left ventricles of rats with volume overload due to severe aortic valve regurgitation. We report that many genes (related to the extra-cellular matrix components) are up-regulated in the LV of AR rats and that this up-regulation persists from the acute to the chronic phase of the disease. A drug combination targeting both the -adrenergic and renin-angiotensin systems was able to prevent the over-expression of some genes such as those of natriuretic peptides (ANP and BNP), collagens I and 3, fibronectin, CTGF and TGF2.
Our AR rats develop a severe LV hypertrophy that can be sustained for a long period of time before heart failure occurs (31). Our model is not a model of rapid heart failure such as the aorto-caval fistula model (9) but a one of well tolerated severe volume overload. It may not be surprising that only a rather modest amount of genes were shown to be regulated in our array experiment compared to what has previously been published in more drastic heart failure models (24) . Moreover, our array results leave the impression that most gene expression changes originated more likely from fibroblasts than from cardiac myocytes. It is however difficult to infer completely physiological consequences to these changes. In addition, profiling gene expression may not be the method of and control rats and this with a similar extent of dilation compared to the latter study.
Moreover, several genes such as ANP, BNP, Collagen 1, skeletal muscle -actin, LOXlike protein among others which were shown previously to be modulated in the aortocaval shunting model were also modulated in our study (25) .
The animals included in our study protocols all had more than 65% of regurgitation which is considered clearly severe in humans. They all developed important LV dilation and hypertrophy but remained with a normal or close to normal ejection fraction.
Although the array used may be one factor explaining this rather modest effect of AR on LV gene expression compared to previous studies, the nature of the volume overload is probably a more important factor. In addition, levels of changes in mRNA expression as evaluated by qRT-PCR were not different than those estimated with the array.
Compared to the aortocaval fistula model which affects directly both right and left heart chambers and is associated with early heart failure, our model of volume overload is centered principally on the LV and affects the right chambers of the heart and the lungs rather modestly. Our model relates to a more frequent clinical condition of volume overload which is known to evolve over decades before the apparition of clinical symptoms requiring valve replacement. Unlike gene expression profiling in cultured neonatal cardiomyocytes stretching (an in vitro model of isolated volume overload (16)) results obtained from a whole organ in a live animal trying to preserve its homeostasis and tending to reach a compensated state should lead to less strongly modulated genes.
An interesting feature highlighted by our study is the chronic activation of the extracellular matrix remodeling in the LV. Although AR is usually not associated with 16 severe myocardial collagen deposition, it is to be noted that at least 8 collagen genes were up-regulated. We observed here as in the past (19) , that peri-vascular fibrosis tended to be increased while elsewhere in the myocardium, there was no marked accumulation of collagen. In addition, genes encoding for fibronectin, fibrillin, elastin and TIMP1 amongst others were all activated in the LV of AR rats. The implication for this observation points towards a constant state of LV ECM remodeling that is still active at later times even when LV hypertrophy evolves at a slower rate. One can propose that the myocardium is either always in a constant state of remodeling or that once some "compensated" form of LV hypertrophy settles then the process of fibrosis accumulation (other than in the vicinity of blood vessels) takes place, a phenomenon we observed in older AR rats (31) . One limitation of this study in this regard is that the gene expression analysis could only be performed on tissues from surviving animals and this is especially important in the 12-month protocol where survival rate of AR animals was down to 40%. This can thus bias the results towards a probably less severe situation since only animals which coped well with the important volume overload were investigated.
Among the genes shown to be up-regulated in the AR animals, it is interesting to note the rather important stimulation of the CTGF and TGF2. In the heart, CTGF can be produced both by cardiomyocytes and fibroblasts (12; 24) . This multifunctional peptide which synthesis is often under TGF control is believed to be associated with myocardial fibrosis (11) through its ability to increase expression of fibronectin and collagens I and III, a situation we observed here. CTGF also has been shown to induce hypertrophy in rat neonatal cardiomyocytes via the Akt pathway making it an interesting target to study in the future (17) . This study also highlights that aiming at both the 1-adrenegic and the renin-angiotensin system is an interesting avenue to explore in the treatment of chronic aortic regurgitation and that this approach is also based on molecular observations. We showed that gene expression of several ECM proteins as well as that of growth factors associated with myocardial fibrosis can be normalized using a combination of metoprolol and captopril.
We observed in previous studies that these drugs independently were effective in slowing loss of cardiac function, development of hypertrophy and fibrosis and in the case of metoprolol, improving survival (30) (31) (32) .
The identification in the present study of new molecular players that are regulated during LV eccentric hypertrophy caused by severe AR opens new avenues of research in the field and new ways to assess the effectiveness of a therapeutic intervention in our model.
Among the new molecular players identified in this study, it is worth mentioning Dscr1 (MCIP; modulatory calcineurin-interacting protein) and S100a1. Dscr1/MCIP which was first believed to be a negative regulator of calcineurin pro-hypertrophic signaling (thus protective for the heart) was more recently shown to be a calcineurin signaling facilitator (34; 35; 39) . The Dscr1/MCIP up-regulation during the first 6 months observed here hints towards a calcineurin implication in the development of the eccentric LV hypertrophy caused by a chronic volume overload. Calcineurin signaling has been more linked in the past to pressure-overload hypertrophy (37) and was observed in mitral valve regurgitation in humans to be unregulated (8) .
S100a1 gene expression was down-regulated in AR LV of our animals at every time point observed. The S100a1 protein has been shown to help calcium cycling in cardiac 18 myocytes thus helping contraction (1; 26; 28) . Gene expression of S100a1 has been shown to be decrease in heart failure (18; 28) and to help restore contractility by gene therapy in a heart failure model (1; 27) . It is interesting here to note that in our AR rat model, the evolution towards heart failure has seldom happened and most of the deaths observed were sudden thus probably caused by fatal arrhythmias. The significance of the down-regulation of this inotropic molecule, S100a1, in our model is thus intriguing and deserves more attention.
In conclusion, we have performed a gene expression profiling in the LV of rats with severe AR and showed for an important subset of modulated genes at two weeks that this regulation persisted in time and could be normalize by -blockade and ACEi combination therapy Table 4 . Genes down-regulated in the LV of rats with severe aortic valve regurgitation. 
